| VHL | Von Hippel-Lindau Syndrome = Cerebelloretinal Hemangioblastomatosis |
|---|---|
| HLD | hepatolenticular degeneration; herniated lumbar disk; Hippel-Lindau disease; hypersensitivity lung d... |
| HLS | Health Learning System; Hippel-Lindau syndrome |
| VHL | von Hippel-Lindau [syndrome] |
| VHL | Van Hippel-Lindau disease |
|---|---|
| VHL | Von Hippel Lindau |
| VHLD | Von Hippel Lindau disease |
| VHL | Von Hippel-Lindau syndrome |
| Lindau's disease | <radiology> Retinocerebellar angiomatosis, phakomatosis, autosomal dominant (variable penetrance), haemangioblastoma: most frequent cause of death, cerebellar (most common), also medullary and spinal, retinal angiomatosis (45%), renal cell carcinoma: 2nd most common cause of death, pheochromocytoma (17%), cortical renal cysts (75%), cysts in virtually any organ, renal/liver haemangioma/adenoma, pancreatic cystic neoplasms, isleT-cell tumours, paraganglioma (12 Dec 1998) |
|---|---|
| Lindau's tumour | <oncology, tumour> A haemangioma, or type of tumour composed of blood vessel or angioblast cells, which occurs in the brain. (09 Oct 1997) |
| von hippel-lindau disease | <disease> A congenital disease characterised by the development of blood vesse ltumours in the retina of the eye and in the brain, lesions and cysts canalso develop in the spina lcord, pancreas, kidneys, and other organs. (09 Oct 1997) |
|---|---|
| von hippel-lindau syndrome | <radiology> Retinocerebellar angiomatosis, phakomatosis, autosomal dominant (variable penetrance), haemangioblastoma: most frequent cause of death, cerebellar (most common), also medullary and spinal, retinal angiomatosis (45%), renal cell carcinoma: 2nd most common cause of death, pheochromocytoma (17%), cortical renal cysts (75%), cysts in virtually any organ, renal/liver haemangioma/adenoma, pancreatic cystic neoplasms, isleT-cell tumours, paraganglioma (12 Dec 1998) |
| hippel-lindau disease | A syndrome transmitted as an autosomal dominant trait and characterised chiefly by angiomata of the retina and haemangioblastoma of the cerebellum and walls of the fourth ventricle. Ocular complications are often present, as are haemangiomas of the spinal cord, face, and other sites. Symptoms may not be apparent until the third decade in life. (12 Dec 1998) |
| syndrome, von hippel-lindau | The cardinal features of von hippel-lindau (vhl) syndrome are benign blood-vessel tumours that most typically affect the eye and the brain. The eye tumours are termed angiomata and are in the retina. The brain tumours are termed haemangioblastoma and are in the cerebellum. Vhl is complex. There can also be blood-vessel tumours (haemangiomata) in the spinal cord, adrenal glands, liver, and lungs. Pheochromocytoma (a benign tumour of adrenal-like tissue) occurs in some patients. The combination of high blood pressure (hypertension) with angioma may cause bleeding under the skull (subarachnoid haemorrhage). Kidney tumours (like hypernephromas) may be malignant and metastasize. An abnormal elevation of red blood cells (polycythemia) can be due to the haemangioblastoma of the cerebellum or the hypernephroma. Multiple cysts can occur in the pancreas and kidneys. Patients with kidney problems or pancreatic cysts do not have pheochromocytoma, and visa versa. Lab findings in vhl may include high calcium (hypercalcaemia) and low potassium (hypokalaemia) occurring with the pheochromocytoma. Vhl is inherited as an autosomal dominant trait. The gene on one of the non-sex chromosomes is dominant over the normal gene with which it is paired so that one vhl gene is sufficient to cause the vhl syndrome. If a person has vhl, the chance for each of their children to receive the vhl gene is one-half (50%). The vhl gene has been mapped to chromosome 3 (the 3rd volume in the book of life) in region 3p26-p25. The vhl gene has the characteristics of a tumour-suppressor gene. The person with vhl inherits one inactive copy of the vhl gene (a germline mutation) from one of their parents. But the normal gene with which it is paired is still enough to suppress the formation of a tumour. Then, in one cell in the vhl patient's body, another mutation (a somatic mutation) occurs, inactivating the vhl gene. Thus, both copies of the vhl gene are inactivated and a tumour arises in the vhl patient. The syndrome is named for the german ophthalmologist eugen von hippel who described the charcteristic eye blood-vessel tumours in 1904 and the swedish pathologist arvid lindau who recognised the association between the eye tumours and the blood-vessel tumours of the cerebellum and other parts of the central nervous system in 1926-7. (12 Dec 1998) |
| Lindau | Arvid, Swedish pathologist, 1892-1958. See: Lindau's disease, Lindau's tumour, von Hippel-Lindau syndrome. (05 Mar 2000) |
| lindau-von hippel syndrome | <syndrome> The cardinal features of what is more commonly called von hippel-lindau (vhl) syndrome are benign blood-vessel tumours that most typically affect the eye and the brain. The eye tumours are termed angiomata and are in the retina. The brain tumours are termed haemangioblastoma and are in the cerebellum. Vhl is complex. There can also be blood-vessel tumours (haemangiomata) in the spinal cord, adrenal glands, liver, and lungs. Pheochromocytoma (a benign tumour of adrenal-like tissue) occurs in some patients. The combination of high blood pressure (hypertension) with angioma may cause bleeding under the skull (subarachnoid haemorrhage). Kidney tumours (like hypernephromas) may be malignant and metastasize. An abnormal elevation of red blood cells (polycythemia) can be due to the haemangioblastoma of the cerebellum or the hypernephroma. Multiple cysts can occur in the pancreas and kidneys. Patients with kidney problems or pancreatic cysts do not have pheochromocytoma, and visa versa. Lab findings in vhl may include high calcium (hypercalcaemia) and low potassium (hypokalaemia) occurring with the pheochromocytoma. Vhl is inherited as an autosomal dominant trait. The gene on one of the non-sex chromosomes is dominant over the normal gene with which it is paired so that one vhl gene is sufficient to cause the vhl syndrome. If a person has vhl, the chance for each of their children to receive the vhl gene is one-half (50%). The vhl gene has been mapped to chromosome 3 (the 3rd volume in the book of life) in region 3p26-p25. The vhl gene has the characteristics of a tumour-suppressor gene. The person with vhl inherits one inactive copy of the vhl gene (a germline mutation) from one of their parents. But the normal gene with which it is paired is still enough to suppress the formation of a tumour. Then, in one cell in the vhl patient's body, another mutation (a somatic mutation) occurs, inactivating the other vhl gene. Thus, both copies of the vhl gene are inactivated and a tumour arises in the vhl patient. The syndrome is named for the german ophthalmologist eugen von hippel who described the charcteristic eye blood-vessel tumours in 1904 and the swedish pathologist arvid lindau who recognised the association between the eye tumours and the blood-vessel tumours of the cerebellum and other parts of the central nervous system in 1926-7. (12 Dec 1998) |
| Lindau's d. |
von Hippel-Lindau d.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
|---|---|
| Lindau's disease, tumor |
see von Hippel-Lindau disease, under disease, and see hemangioblastoma.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
| Lindau's t. |
hemangioblastoma.
출처: www.mercksource.com/pp/us/cns/cns_health_library.j...
|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|